Patents by Inventor Douglas A. Livingston

Douglas A. Livingston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and Compositions for Highly Sensitive Detection of Molecules
    Publication number: 20240110870
    Abstract: Disclosed are methods, kits, and compositions for the highly sensitive detection of molecules. The methods, kits, and compositions are useful in determining concentrations of molecules in samples to levels of 1 femtomolar, 1 attomolar, or lower. The methods, kits, and compositions also allow the determination of concentration over a wide range, e.g., 7-log range, without need for sample dilution.
    Type: Application
    Filed: August 25, 2023
    Publication date: April 4, 2024
    Inventors: Philippe J. Goix, Robert Puskas, John Todd, Richard A. Livingston, Douglas Held
  • Highly Sensitive System and Method for Analysis of Troponin
    Publication number: 20240085430
    Abstract: The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.
    Type: Application
    Filed: September 6, 2023
    Publication date: March 14, 2024
    Inventors: Philippe J. Goix, Robert Puskas, John Todd, Richard Livingston, Douglas Held, Allan H.B. Wu
  • Chemically-defined non-polymeric valency platform molecules and conjugates thereof
    Publication number: 20070254851
    Abstract: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.
    Type: Application
    Filed: October 2, 2006
    Publication date: November 1, 2007
    Inventors: Stephen Coutts, David Jones, Douglas Livingston, Lin Yu
  • Chemically defined non-polymeric valency platvorm molecules and conjugates thereof
    Publication number: 20050026856
    Abstract: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.
    Type: Application
    Filed: July 30, 2003
    Publication date: February 3, 2005
    Inventors: Stephen Coutts, David Jones, Douglas Livingston, Lin Yu
  • Chemically-defined non-polymeric valency platform molecules and conjugates thereof
    Patent number: 5633395
    Abstract: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: May 27, 1997
    Assignee: La Jolla Pharmaceutical Company
    Inventors: Stephen M. Coutts, David S. Jones, Douglas A. Livingston, Lin Yu
  • Chemically-defined non-polymeric valency platform molecules and conjugates thereof
    Patent number: 5606047
    Abstract: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: February 25, 1997
    Assignee: La Jolla Pharmaceutical Company
    Inventors: Stephen M. Coutts, David S. Jones, Douglas A. Livingston, Lin Yu
  • Chemically-defined non-polymeric valency platform molecules and conjugates thereof
    Patent number: 5552391
    Abstract: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.
    Type: Grant
    Filed: November 15, 1993
    Date of Patent: September 3, 1996
    Assignee: La Jolla Pharmaceutical Company
    Inventors: Stephen M. Coutts, David S. Jones, Douglas A. Livingston, Lin Yu
  • Intermediates for providing functional groups on the 5' end of oligonucleotides
    Patent number: 5391785
    Abstract: Phosphoramidites of the formula ##STR1## where R is a base-labile protecting group, R.sup.1 and R.sup.
    Type: Grant
    Filed: July 15, 1992
    Date of Patent: February 21, 1995
    Assignee: La Jolla Pharmaceutial Company
    Inventors: David S. Jones, John P. Hachmann, Michael J. Conrad, Stephen Coutts, Douglas A. Livingston
  • Steroidal 17.alpha.-silyl ethers and process to corticoids and progesterones
    Patent number: 4977255
    Abstract: 17.beta.-Cyano-17.alpha.-hydroxy steroids (I) are transformed to 17.alpha.-halo silyl ethers (II) which are intermediates useful in the production of progesterones (V), 17-hydroxyprogesterones (VI), corticoids (VII) and 21-halo corticoids (III) which can readily be transformed to corticoids (VII).
    Type: Grant
    Filed: April 7, 1989
    Date of Patent: December 11, 1990
    Assignee: The Upjohn Company
    Inventors: Douglas A. Livingston, Bruce A. Pearlman, Scott Denmark
  • 17.beta.-cyano-9.alpha.,17.alpha.-dihydroxyandrost-4-en-3-one
    Patent number: 4921638
    Abstract: The invention is the compound 17.beta.-cyano-9.alpha., 17.alpha.-dihydroxyandrost-4-en-3-one (I) which is particularly useful as an intermediate in the production of the 17.alpha.-halo silyl ethers (II).
    Type: Grant
    Filed: October 3, 1988
    Date of Patent: May 1, 1990
    Assignee: The Upjohn Company
    Inventors: Douglas A. Livingston, Bruce A. Pearlman, Scott Denmark, Joel E. Huber
  • Thesis of 7-halo-7-deoxylincomycins
    Patent number: 4710565
    Abstract: Process for preparing clindamycin and analogs thereof by reacting lincomycin or an analog thereof with a dimethylformamide and an excess of thionyl halide.
    Type: Grant
    Filed: January 24, 1986
    Date of Patent: December 1, 1987
    Assignee: The Upjohn Company
    Inventors: Douglas A. Livingston, Janet E. Petre
  • Synthesis of 7-halo-7-deoxylincomycins
    Patent number: 4568741
    Abstract: An improved process for preparing 7-halo-7-deoxylincomycins and analogs thereof. The compounds prepared have anti-bacterial activity.
    Type: Grant
    Filed: May 15, 1984
    Date of Patent: February 4, 1986
    Assignee: The Upjohn Company
    Inventor: Douglas A. Livingston
  • Packaging system
    Patent number: D556566
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: December 4, 2007
    Assignee: Remington Health Products, L.L.C.
    Inventors: William E. Steele, IV, George E. Steele, Phillip Douglas Livingston
  • Package
    Patent number: D572581
    Type: Grant
    Filed: September 13, 2007
    Date of Patent: July 8, 2008
    Assignee: Remington Health Products L.L.C.
    Inventors: William E. Steele, IV, George E. Steele, Phillip Douglas Livingston